DC Field | Value | Language |
dc.contributor.author | Cavalji, Daria | - |
dc.date.accessioned | 2020-07-02T05:09:20Z | - |
dc.date.available | 2020-07-02T05:09:20Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | CAVALJI, Daria. The pharmacotherapeutic aspects of metabolic disease caused by hypertension. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 260. | en_US |
dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf | - |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/10821 | - |
dc.description | Department of Pharmacology
and Clinical Pharmacy,
Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova | en_US |
dc.description.abstract | Introduction. Among cardiovascular diseases with an important impact on the general
population, hypertension (HTA) is also found. Considering the association of HTA with risk
factors such as diabetes and the level of impact on public health spending, the European Society
of Hypertension has developed a guide to the evaluation and treatment of hypertension and
associated diseases. Starting from the idea that atherosclerosis is the most common cause of
hypertension and that at the base of the pathophysiology of atherosclerosis is the dyslipidemic
process, and following dietary habits with excess fat and often consumption excess alcohol,
accompanied by smoke and lesser movement and all of these are spreading to younger age, we
have given greater interest to these findings.
Aim of the study. To identify the risk factors and their influence on hypertension in a group of
100 patients over the two years.
Materials and methods. The work was based on the random incorporation of displaced patients
from the Public Health Care Institution Institute of Cardiology from Chisinau after the screening
of more than 200 clinical observation sheets.
Results. We calculated the mean value of cholesterol, LDL-C, HDL-C, triglycerides and each of
these were reported based on glucose, blood pressure, body mass index, smokers, personal
history of early cardiopathy, and their dispersion according to the age in order to be able to
capture the maximum incidence and to appreciate the extent to which new behavioral
movements (increased smoking among women) have a consequence, and depending on the
background of the sick, knowing that in rural areas the diet is richer in animal fat, but physical
effort is more engaging, while in urban areas food often becomes hypercaloric compared to the
lower level of exercise. We compared dynamically, the evolution of clinical symptoms, the value
of laboratory and imaging results, and the relation to smoking, respectively the body mass index,
as well as the measurement of their results in the number of coronary events.
Conclusion. Metabolic syndrome includes symptoms related to a hyperactivity of the
sympathetic system, with hypertension being the most important of these disorders, but also
obesity, insulin resistance, glucose intolerance, and blood lipid abnormalities. According to the
analysis of predisposing factors in the occurrence of metabolic syndrome-induced HTA,
dyslipidemia was the most common risk factor (87,6%), obesity was 66%, smoking at 58,0%,
and hyperglycemia at 51,6%. Basic treatment includes inhibitors of the angiotensin converting
enzyme, β-blockers, angiotensin receptor blockers (sartans), antidiabetic agents, platelet
antiaggregants and hypolipemics. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | hypertension | en_US |
dc.subject | diabetes | en_US |
dc.subject | metabolic syndrome | en_US |
dc.subject | dyslipidemia | en_US |
dc.title | The pharmacotherapeutic aspects of metabolic disease caused by hypertension | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2018
|